Prescription drug · ANDA
Ganirelix Acetate NDC 68083-472
Ganirelix acetate 250 ug/.5mL · Injection, Solution · Subcutaneous · Gland Pharma Limited
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 68083-472-01 | 6808304720168083047201 | 1 BLISTER PACK in 1 CARTON (68083-472-01) / 1 SYRINGE, GLASS in 1 BLISTER PACK / 1 mL in 1 SYRINGE, GLASSMarketed from Feb 28, 2023 |
How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Ganirelix Acetate
- Generic name (nonproprietary)
- ganirelix acetate
- Active ingredients
- Ganirelix acetate — 250 ug/.5mL
- Dosage form
- Injection, Solution
- Route
- Subcutaneous
- Labeler
- Gland Pharma LimitedNDC labeler code 68083
- Product type
- Prescription drug
- Marketing category
- ANDA — Abbreviated New Drug Application (generic)Application ANDA 215658
- Marketing start
- Listing expires
- Other FDA classes
- Decreased GnRH Secretion (Physiologic effect)Gonadotropin Releasing Hormone Receptor Antagonists (Mechanism)
- Identifiers
- Product ID 68083-472_9d647fa7-adc3-4767-a8e5-1b44b07cdd34SPL ID 9d647fa7-adc3-4767-a8e5-1b44b07cdd34SPL set ID cad7c09c-234b-4e73-b460-a1b1f7adc28dRxCUI 855200UNII 56U7906FQWUPC 0368083472016
- Pharmacologic class
- Gonadotropin Releasing Hormone Receptor Antagonist
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.
- Administration
Drug administration (CPT 96360–96549)
When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.
- NDC on a medical claim
N468083047201followed by a unit qualifier and the quantityPackage 68083-0472-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
INDICATIONS AND USAGE Ganirelix Acetate Injection is indicated for the inhibition of premature LH surges in women undergoing controlled ovarian hyperstimulation.
Excerpt only. Read the full label for complete information.
About NDC 68083-472
- What is NDC 68083-472?
- 68083-472 is the product NDC for Ganirelix Acetate, Ganirelix acetate 250 ug/.5mL injection, solution, listed with the FDA by Gland Pharma Limited. It has 1 package NDC, shown above in 10- and 11-digit form.
- What drug is associated with this NDC?
- Ganirelix Acetate.
- What is the active ingredient?
- Ganirelix acetate.
- Who is the labeler?
- Gland Pharma Limited, NDC labeler code 68083. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
- What other NDCs exist for Ganirelix Acetate?
- 8 other product NDCs are listed under this name. See all Ganirelix Acetate NDCs.
- Is there a related HCPCS / J-code?
- Not in Med-Code's curated HCPCS directory. See Billing references above.
Related NDCs: other Ganirelix Acetate products
Other finished products listed under the same name: strengths, forms and labelers.
| Product | Strength | Form · route | Labeler | Product NDC | Package NDCs (11-digit) |
|---|---|---|---|---|---|
| Ganirelix Acetate | Ganirelix acetate 250 ug/.5mL | Injection, SolutionSubcutaneous | Mullan Pharmaceutical Inc. | 83301-0082 | 83301-0082-01 |
| Ganirelix Acetate | Ganirelix acetate 250 ug/.5mL | Injection, SolutionSubcutaneous | Qilu Pharmaceutical Co., Ltd. | 67184-0574 | 67184-0574-01 |
| Ganirelix Acetate | Ganirelix acetate 250 ug/.5mL | InjectionSubcutaneous | Xiromed LLC | 70700-327 | 70700-0327-98 |
| Ganirelix Acetate | Ganirelix acetate 250 ug/.5mL | Injection, SolutionSubcutaneous | Lupin Pharmaceuticals, Inc. | 70748-274 | 70748-0274-01 |
| Ganirelix Acetate | Ganirelix acetate 250 ug/.5mL | InjectionSubcutaneous | Fresenius Kabi USA, LLC | 65219-028 | 65219-0028-05 |
| Ganirelix Acetate | Ganirelix acetate 250 ug/.5mL | InjectionSubcutaneous | Amphastar Pharmaceuticals, Inc. | 0548-5001 | 00548-5001-00 |
| Ganirelix Acetate | Ganirelix acetate 250 ug/.5mL | Injection, SolutionSubcutaneous | Meitheal Pharmaceuticals Inc. | 71288-554 | 71288-0554-80 |
| Ganirelix Acetate | Ganirelix acetate 250 ug/.5mL | Injection, SolutionSubcutaneous | Organon LLC | 78206-138 | 78206-0138-02 |
Other NDCs under ANDA 215658
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Ganirelix Acetate | Ganirelix acetate 250 ug/.5mL | InjectionSubcutaneous | Fresenius Kabi USA, LLC | 65219-028 |
| Ganirelix Acetate | Ganirelix acetate 250 ug/.5mL | InjectionSubcutaneous | Xiromed LLC | 70700-327 |